Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Clinical trial NCT03039114 · COMPLETED
Trial details
- NCT number
- NCT03039114
- Sponsor
- Incyte Corporation
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-02-15
- Primary completion
- 2021-03-30
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.